- Agenus (NASDAQ:AGEN) announced new data for balstilimab, an anti-PD-1 antibody, and AGEN2373, a CD137 agonist antibody as contained in abstracts that will be part of two poster presentations scheduled at the American Society for Clinical Oncology (ASCO) Annual Meeting 2021.
- In a Phase 2 trial for patients with recurrent or metastatic cervical cancer, “balstilimab has shown expanded clinical activity,” the company said.
- Responses were seen in both PD-L1 positive and PD-L1 negative tumors indicating its differentiated activity profile as approved anti-PD-1 antibodies lead to almost no response in PD-L1 negative patients, according to a statement from Agenus.
- In the first-in-human study for AGEN2373 in patients with advanced solid tumors, the experimental therapy was well tolerated. No liver toxicities were seen and no dose-limiting toxicities were observed at doses up to 3 mg/kg, the company said.
- Out of 19 patients who received the treatment as a monotherapy, five demonstrated stable disease. One indicating stable disease had metastatic leiomyosarcoma, and the patient was heavily pretreated and failed to respond to a prior combination checkpoint immunotherapy.
- In April, Agenus announced the submission of Biologics License Application (BLA) to the FDA for accelerated approval of balstilimab in recurrent or metastatic cervical cancer.
- #ASCO21